Team leader : Dr Philippe P Juin (lab director)

Research Projects

The objectives of the SATE team, based at IRS-UN and ICO Saint Herblain, are to describe the molecular mechanisms and reprogramming pathways that, in response to various types of cellular stress, participate in the organization of epithelial tumors as a pseudo-organ; to understand the signals involved in the escape from tumor suppression; and to identify therapeutic approaches to reactivate this suppression.

We focus our research, albeit non-exclusively, on breast carcinoma. We concentrate on the effects of stress on mitochondrial integrity and cell survival (mitochondrial apoptosis pathway in particular) and on the mechanisms of resolution of these stresses during the progression and treatment of these epithelial cancers.

Our positioning at the interface of upstream research and transfer research allows us, by taking full advantage of the complementary expertise of the researchers, clinicians and veterinarians who constitute our team, to study samples derived from patients in addition to relevant models of cancer pathology.

We are organized into four interconnected working groups, exploring:

  1. The biochemical and cellular determinants of mitochondrial priming/processing in individual cells and in populations (L. Maillet, S. Barillé-Nion, M. Le Breton) 
  2. The role of mitochondrial stress and cell death on the organization of epithelial diversity and the influence of primary ciliogenesis in cancer stem cell resistance (F. Gautier, V. Guen) 
  3. Reciprocal influences between heterotypic intercellular communications in the microenvironment, mitochondrial signaling and cell survival (F. Souazé)    
  4. Epigenetic events related to mitochondrial signaling and cell survival in tumor ecosystems (P-F. Cartron, L.Lalier)
                                                                                                
CAFs                                                       
Cancer Associated Fibroblasts (CAFs)                                                    "Organemone" by Floriane
by immunocytochemistry
                                                       


Our common objectives are to:
– identify novel mechanisms regulating cell death/survival balance in malignant cell populations
– characterize what determines, and what is determined, by mitochondrial stress in tumor ecosystems
– define cellular targets, the therapeutic window of agents targeting cell survival mechanisms, and longitudinal markers of response to these agents

To reach them, we take advantage of clinically relevant models, including organotypic cultures, organoids and xenografts derived from patients (PDX). We use single cell analysis of breast tumors and work closely with bioinformaticians for the analytical part. The team members actively participate in many networks such as SIRIC ILIAD, CGO (co-head of the CasTHor and NET networks, CNRS GDR Micronit) to expand our know-how and share our expertise with the scientific community.
One of the strengths of our team is that it brings together scientists with very diverse backgrounds going from cell biology to molecular biology with a clear attraction for innovation and new technologies. 
 

Equipe 7 photo
 

Latest news

  The EpiBesancon Congress took place on May 10 and 11, 2002, bringing together hundreds of researchers in epigenetics. Next edition in 2024 stay tuned ...

  Thanks to the patient association "Entraide Cancer 44" to support our research projects on breast cancer!


Lab members

Researchers

Philippe P Juin, DR INSERM (HDR)

Sophie Barillé-Nion, CR INSERM (HDR)
Laurent Maillet, CR INSERM (HDR)
Frédérique Souazé, CR INSERM (HDR)
Pierre-François Cartron, CR INSERM (HDR)
Vincent Guen, CR INSERM
Magali Le Breton, Associated Professor 
Lisenn Lalier, CR ICO
Fabien Gautier, CR ICO


Technical and administrative staff

Floriane Briand, AI
Aurélie Fétiveau, TR
Julie Roul, TR
Arulraj Nadaradjane, TR
Gwenola Cartron, Project manager, ICO

Medical associated staff

Mario Campone, PU-PH ICO
Pascal Jézéquel, PH ICO
Jean-Sébastien Frenel, PH ICO
Olivier Kerdraon, PH ICO
Judith Raimbourg, PH ICO
Marie Robert, PH ICO
Frédérique Nguyen, Associated professor ONIRIS

PhD students and Post docs

Lisa Nocquet, PhD student
Florestan Courant, PhD student
Alison Dumont, PhD student
Florian Chocteau, PhD student

Recent key publications

 
PARTNERSHIP LABELS FUNDINGS
ICO Labex IGO INCa arc CGO

Current and past theses

CURRENT

Florestan Courant: Cross-species differences or similarities in epigenetic mechanisms induced by pesticides or chemotherapeutic agents. (3rd year)

Alison Dumont: Heterogeneity in the response of breast tumors to antimitotics: What impacts on treatment resistance and immune response?

Lisa Nocquet: Implication of BCL-xL and MCL-1 in the metabolic control of cell death by cancer-associated fibroblasts in triple negative breast cancer

Florian Chocteau: Metastatic process in breast cancer after chemotherapy treatment:  Immune microenvironment and tumor clonal evolution in the metastatic niche

PAST 

Nina Belaid: Modulation of KRAS activity by BCL-xL: mechanistic aspects and therapeutic implications. Defense on May 18, 2022

Thomas Bonneaud: Consequences of pharmacological targeting of MCL-1 on the myofibroblastic phenotype of breast cancer-associated fibroblasts. Defense on December 3, 2021

Margot Lavy: Regulating myeloid cell activity in tumors through Resolvlne receptors : chemR23. Defense on December 13, 2021

Manon Duforestel: Study of epigenetic mechanisms and dynamics in glioblastoma multiforme during the acquisition of temozolomide resistance.  Defense on September 17, 2021

Steven Lohard: STING-dependent paracriny shapes apoptotic priming of breast tumors in response to antimitotic treatment. Defense on May 3, 2019

Josephine Briand: Glioblastoma and epigenetics: from prevention to development of new treatments. Defense on December 12, 2019

Kevin Louault: Role of Cancer-associated fibroblast in apoptosis resistance in breast cancers. Defense on December 19, 2018

Céline Vuillier: Mitochondrial apoptosis regulated by E2F1. Involvement of the E2F1 mitochondrial targeting and interactions with the Bcl-2 Family anti-apoptotic members. Defense on December 19, 2016

Jessie Pécot: BCLxL dependence of cancer cells. Targeting of the dynamic BCLxL/PUMA/BAX network. Oncogenic pathways regulated by the non canonical RAS/BCLxL interaction (October 2015)

Eloise Véquaud: Study of mammary cancer cells response to silencing of surviving by RNA interference or pharmacological targeting: highlighting oh homologous recombination regulation by survivin. (December 2014)

Master degrees

From 2019
Aurore Dupuy 2021/22: Master 2 "Biologie Moléculaire et Cellulaire", University of Rennes 1, France. Investigating the role of the primary cilium in mammary gland remodeling during the reproduction cycle.
Maxime Richomme 2021/22: Master 2 "Biologie, Biotechnologie et Recherche Thérapeutique", Nantes University
Klara Edern 2021/22: Equivalent Master 2 Bioinformatics at Ecole Centrale de Nantes "High throughput data analysis to predict tumor cell fate and/or the existence of therapeutic vulnerabilities"
Morgane Allory 2021/22: Master 2 Biologie Santé parcours "Interactions cellulaires et Application thérapeutiques",  Angers University.  Identification of epigentic and/or epitranscriptomic biomarkers predictive of vulnerabilities to drugs/targeted therapy molecules.
Chloé Lefebvre 2021/22: Master 2 "Biologie, Biotechnologie et Recherche Thérapeutique", Nantes University. Role of MCL-1 in myofibroblast phenotype and chemoresistance of fibroblasts associated with breast cancers.
Hugo Weber 2020/21: Master 2 « Oncologie Moléculaire et Biothérapies », Limoges University. Effect of irradiation on the sensitivity of CAFs and breast adenocarcinoma cancer cells to BH3 mimetics: Evaluation of their therapeutic potential as senolytic agents.
Yuna Landais 2020/2021: Equivalent Master 2 Bioinformatics at Ecole Centrale de Nantes. "Study of mitochondrial genome methylation by direct nanopore sequencing"
Elen Goujon 2020/2021: Equivalent Master 2 Bioinformatics at Ecole Centrale de Nantes. "Development of biomedical data analysis pipelines in oncology"
Piera Grisolina 2019/2020: ERASMUS. Master 2 "Biologie Moléculaire et Cellulaire" University of Rennes 1/Tieste University, Italy. Investigating the molecular mechanisms by which EMT programs induce primary ciliogenesis. 
Alison Dumont 2019/2020: Master 2 "Biologie, Biotechnologie et Recherche Thérapeutique", Nantes University: Induction of NOXA pro-apoptotic protein expression in response to Paclitaxel in breast tumors: Regulome analysis of its gene transcription.
Louis Paré 2019/2020: Equivalent Master 2 Bioinformatics at Ecole Centrale de Nantes. "Cinetic study of the resistance of anti-tumor treatments by epigenetic genome analysis"

Publication list

2022

  • Garnier D, Ratcliffe E, Briand J, Cartron PF, Oliver L, Vallette FM. The Activation of Mesenchymal Stem Cells by Glioblastoma Microvesicles Alters Their Exosomal Secretion of miR-100-5p, miR-9-5p and let-7d-5p. Biomedicines. 2022 Jan 6;10(1):112.
  • Wilson MM, Callens C, Le Gallo M, Mironov S, Ding Q, Salamagnon A, Chavarria TE, Viel R, Peasah AD, Bhutkar A, Martin S, Godey F, Tas P, Kang HS, Juin PP, Jetten AM, Visvader JE, Weinberg RA, Attanasio M, Prigent C, Lees JA, Guen VJ. An EMT-primary cilium-GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis. Sci Adv. 2021 Oct 29;7(44):eabf6063. 
  • Lalier L, Vallette F, Manon S. Bcl-2 Family Members and the Mitochondrial Import Machineries: The Roads to Death. Biomolecules. 2022 Jan 19;12(2):162. 

2021

  • Lavy M, Gauttier V, Poirier N, Barillé-Nion S, Blanquart C. Specialized Pro-Resolving Mediators Mitigate Cancer-Related Inflammation: Role of Tumor-Associated Macrophages and Therapeutic Opportunities. Front. Immunol., 30 June 2021 | https://doi.org/10.3389/fimmu.2021.702785.
  • Ben Azzouz F, Michel B, Lasla H, Gouraud W, François AF, Girka F, Lecointre T, Guérin-Charbonnel C, Juin PP, Campone M, Jézéquel P. Development of an absolute assignment predictor for triple-negative breast cancer subtyping using machine learning approaches. Comput Biol Med. 2021 Feb;129:104171. doi: 10.1016/j.compbiomed.2020.104171.
  • Jézéquel P, Gouraud W, Ben Azzouz F, Guérin-Charbonnel C, Juin PP, Lasla H, Campone M. bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database (Oxford). 2021 Feb 18; 2021:baab007. doi: 10.1093/database/baab007.
  • Tea I, De Luca A, Schiphorst AM, Grand M, Barillé-Nion S, Mirallié E, Drui D, Krempf M, Hankard R, Tcherkez G. Stable Isotope Abundance and Fractionation in Human Diseases. Metabolites. 2021 Jun 9;11(6):370. 
  • Lalier L, Mignard V, Joalland MP, Lanoé D, Cartron PF, Manon S, Vallette FM. TOM20-mediated transfer of Bcl2 from ER to MAM and mitochondria upon induction of apoptosis. Cell Death Dis. 2021 Feb 15;12(2):182. 
  • Wilson MM, Callens C, Le Gallo M, Mironov S, Ding Q, Salamagnon A, Chavarria TE, Viel R, Peasah AD, Bhutkar A, Martin S, Godey F, Tas P, Kang HS, Juin PP, Jetten AM, Visvader JE, Weinberg RA, Attanasio M, Prigent C, Lees JA, Guen VJ. An EMT-primary cilium-GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis. Sci Adv. 2021 Oct 29;7(44):eabf6063.
  • Hazan R, Mori M, Danielian PS, Guen VJ, Rubin SM, Cardoso WV, Lees JA. E2F4's cytoplasmic role in multiciliogenesis is mediated via an N-terminal domain that binds two components of the centriole replication machinery, Deup1 and SAS6. Mol Biol Cell. 2021 Oct 1;32(20):ar1.
  • Duclos M, Prigent C, Le Borgne R, Guen VJ. Three-Dimensional Imaging of Organoids to Study Primary Ciliogenesis During ex vivo Organogenesis. J Vis Exp. 2021 May 14;(171). 
  • Olivier C, Oliver L, Lalier L, Vallette FM. Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress. Front Mol Biosci. 2021 Jan 27;7:620677.

2020

  • Lohard S, Bourgeois N, Maillet L, Gautier F, Fétiveau A, Lasla H, Nguyen F, Vuillier C, Dumont A, Moreau-Aubry A, Frapin M, David L, Loussouarn D, Kerdraon O, Campone M, Jézéquel P, Juin PP, Barillé-Nion S. STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment. Nature Communications. 2020 11:259. doi.org/10.1038/s41467-019-13689-y
  • Lohard S, Juin PP, Barillé-Nion S. Mitotic stress-induced secretome primes cancer cells to apoptosis and maximizes paclitaxel response in breast tumors when combined with BCL-xL-targeting BH3 mimetics. Mol Cell Oncol. 2020 Mar 19;7(3):1735912. doi: 10.1080/23723556.2020.1735912. 
  • Barillé-Nion S, Lohard S, Juin PP: Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses? Biomolecules 2020 Jul 25;10(8):E1109. doi: 10.3390/biom10081109.
  • Nocquet L, Juin PP, Souazé F. Mitochondria at Center of Exchanges between Cancer Cells and Cancer-Associated Fibroblasts during Tumor Progression. Cancers (Basel). 2020 Oct 17;12(10):3017. doi: 10.3390/cancers12103017.
  • Guyon N, Garnier D, Briand J, Nadaradjane A, Bougras-Cartron G, Raimbourg J, Campone M, Heymann D, Vallette FM, Frenel JS, Cartron PF. Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells. Cell Death Dis. 2020 Dec 11;11(12):1048. doi: 10.1038/s41419-020-03224-z.
  • Peixoto P, Cartron PF, Serandour AA, Hervouet E. From 1957 to Nowadays: A Brief History of Epigenetics. Int J Mol Sci. 2020 Oct 14;21(20):7571. doi: 10.3390/ijms21207571. PMID: 33066397; PMCID: PMC7588895.
  • Briand J, Sérandour AA, Nadaradjane A, Bougras-Cartron G, Heymann D, Ory B, Vallette FM, Cartron PF. N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool. Mol Ther Nucleic Acids. 2020 Aug 14;22:72-83. doi: 10.1016/j.omtn.2020.08.010. 
  • Oliver L, Lalier L, Salaud C, Heymann D, Cartron PF, Vallette FM. Drug resistance in glioblastoma: are persisters the key to therapy? Cancer Drug Resist. 2020 Aug 7;3(3):287-301. doi: 10.20517/cdr.2020.29.
  • Briand J, Garnier D, Nadaradjane A, Clément-Colmou K, Potiron V, Supiot S, Bougras-Cartron G, Frenel JS, Heymann D, Vallette FM, Cartron PF. Radiotherapy-induced overexpression of exosomal miRNA-378a-3p in cancer cells limits natural killer cells cytotoxicity. Epigenomics. 2020 Mar;12(5):397-408. doi: 10.2217/epi-2019-0193. 
  • Cheray M, Etcheverry A, Jacques C, Pacaud R, Bougras-Cartron G, Aubry M, Denoual F, Peterlongo P, Nadaradjane A, Briand J, Akcha F, Heymann D, Vallette, FM, Mosser J, Ory B, Cartron PF. Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme. Mol Cancer. 2020 Feb 25;19(1):36. doi: 10.1186/s12943-020-01155-z.
  • Rabé M, Dumont S, Álvarez-Arenas A, Janati H, Belmonte-Beitia J, Calvo GF, Thibault-Carpentier C, Séry Q, Chauvin C, Joalland N, Briand F, Blandin S, Scotet E, Pecqueur C, Clairambault J, Oliver L, Perez-Garcia V, Nadaradjane A, Cartron PF, Gratas C, Vallette FM. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death Dis. 2020 Jan 6;11(1):19. 
  • Duforestel M, Briand J, Bougras-Cartron G, Heymann D, Frenel JS, Vallette FM, Cartron PF. Cell-free circulating epimarks in cancer monitoring. Epigenomics. 2020 Jan;12(2):145-155. doi: 10.2217/epi-2019-0170. 
  • Cartron PF, Cheray M, Bretaudeau L. Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer. Epigenomics. 2020 Jan;12(2):171-177. doi: 10.2217/epi-2019-0169.
  • Guen VJ, Prigent C. Targeting Primary Ciliogenesis with Small-Molecule Inhibitors. Cell Chem Biol. 2020 Oct 15;27(10):1224-1228. .
  • Wilson MM, Weinberg RA, Lees JA, Guen VJ. Emerging Mechanisms by which EMT Programs Control Stemness. Trends Cancer. 2020 Sep;6(9):775-780. 
  • Mignard V, Dubois N, Lanoé D, Joalland MP, Oliver L, Pecqueur C, Heymann D, Paris F, Vallette FM, Lalier L. Sphingolipid distribution at mitochondria-associated membranes (MAMs) upon induction of apoptosis. J Lipid Res. 2020 Jul;61(7):1025-1037.

2019

  • Louault K, Bonneaud TL, Séveno C, Gomez-Bougie P, Nguyen F, Gautier F, Bourgeois N, Loussouarn D, Kerdraon O, Barillé-Nion S, Jézéquel P, Campone M, Amiot M, Juin PP, Souazé F. Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers. Oncogene. 2019 Apr;38(17):3261-3273. doi: 10.1038/s41388-018-0635-z. 
  • Avril P, Vidal L, Barille-Nion S, Le Nail LR, Redini F, Layrolle P, Pinault M, Chevalier S, Perrot P, Trichet V. Epinephrine Infiltration of Adipose Tissue Impacts MCF7 Breast Cancer Cells and Total Lipid Content. Int J Mol Sci. 2019 Nov 11;20(22). pii: E5626.
  • Ramana Murthy AV, Narendar V, Kumar NS, Aparna P, Durga Bhavani AK, Gautier F, Barillé-Nion S, Juin P, Mosset P, Grée R, Levoin N. Targeting PUMA/Bcl-xL interaction by new specific compounds to unleash apoptotic process in cancer cells. Eur J Med Chem. 2019 Jan 15;162:334-347.
  • Briand J, Nadaradjane A, Bougras-Cartron G, Olivier C, Vallette FM, Cartron PF. Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation. Clin Epigenetics. 2019 Nov 14;11(1):159. doi: 10.1186/s13148-019-0759-1. 
  • Duforestel M, Nadaradjane A, Bougras-Cartron G, Briand J, Olivier C, Frenel JS, Vallette FM, Lelièvre SA, Cartron PF. Glyphosate Primes Mammary Cells for Tumorigenesis by Reprogramming the Epigenome in a TET3-Dependent Manner. Front Genet. 2019 Sep 27;10:885. doi: 10.3389/fgene.2019.00885. 
  • Vallette FM, Olivier C, Lézot F, Oliver L, Cochonneau D, Lalier L, Cartron PF, Heymann D. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. Biochem Pharmacol. 2019 Apr;162:169-176. doi: 10.1016/j.bcp.2018.11.004.
  • Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? Drug Discov Today. 2019 Mar;24(3):763-772. doi: 10.1016/j.drudis.2018.11.017.
  • Blanquart C, Linot C, Cartron PF, Tomaselli D, Mai A, Bertrand P. Epigenetic Metalloenzymes. Curr Med Chem. 2019;26(15):2748-2785. 

2018

  • Aira L., Villa E., Colosetti P., Gamas P., Signetti L., Obba S., Proics E., Gautier F., Bailly-Maitre B., Jacquel A., Robert G., Luciano F., Juin P., Ricci J.-E., Auberger P., Marchetti S. The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Bim. Oncogene, (2018) 37(16):2122-2136. 
  • Jézéquel P., Campone M. Comment on “How the evolution of multicellularity set the stage for cancer”. British Journal of Cancer (2018) Réf. HAL: inserm-01823385 
  • Anne Lok, Géraldine Descamps, Benoit Tessoulin, David Chiron, Marion Eveillard, Catherine Godon, Yannick Le Bris, Astrid Vabret, Céline Bellanger, Laurent Maillet, Sophie Barillé-Nion, Marc Gregoire, Jean-François Fonteneau, Steven Le Gouill, Philippe Moreau, Frederic Tangy, Martine Amiot, Agnès Moreau-Aubry, Catherine Pellat-Deceunynck. p53 regulates CD46 expression and measles virus infection in myeloma cells. Blood Advances (2018) 23(2) :3492 Réf. HAL : inserm-01957487 
  • Allègre J., Cartier J., Glorian V., Nathalie D., Dumetier B., Kayaci C., Berthelet J., Gemble S., Vuillier C., Maillet L., Garrido C., Dubrez L. E2F1 binds to the peptide-binding groove within the BIR3 domain of cIAP1 and requires cIAP1 for chromatin binding. PLoS ONE, (2018) 13(10):e0206253.  Réf. HAL: hal-01923499
  • Galluzzi L, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, (2018) 25(3):486-541. 
  • Hedir S, De Giorgi M, Fogha J, De Pascale M, Weiswald LB, Brotin E, Marekha B, Denoyelle C, Denis C, Suzanne P, Gautier F, Juin P, Ligat L, Lopez F, Carlier L, Legay R, Bureau R, Rault S, Poulain L, Oliveira Santos JS, Voisin-Chiret AS. Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode. Eur J Med Chem. 2018 Nov 5;159:357-380.
  • Nadaradjane A, Briand J, Bougras-Cartron G, Disdero V, Vallette FM, Frenel JS, Cartron PF. miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker. Mol Ther Nucleic Acids. 2018 Dec 7;13:642-650. doi: 10.1016/j.omtn.2018.09.007. 
  • Georges S, Calleja LR, Jacques C, Lavaud M, Moukengue B, Lecanda F, Quillard T, Gabriel MT, Cartron PF, Baud'huin M, Lamoureux F, Heymann D, Ory B. Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma. Oncotarget. 2018 Nov 6;9(87):35726-35741.
  • Hervouet E, Peixoto P, Delage-Mourroux R, Boyer-Guittaut M, Cartron PF. Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma. Clin Epigenetics. 2018 Feb 9;10:17. doi: 10.1186/s13148-018-0450-y. 
  • Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre JR, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron PF, Borg C, Hervouet E. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology. 2018 Feb 1;7(5):e1423170. 

2017

 
  • Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP. BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nat Commun. 2017 Oct 24;8(1):1123. doi: 10.1038/s41467-017-01079-1.
  • Céline Vuillier, Steven Lohard, Aurélie Fétiveau, Jennifer Allègre, Cémile Kayaci, Louise E King, Frédérique Braun, Sophie Barillé-Nion, Fabien Gautier, Laurence Dubrez, Andrew P Gilmore, Philippe P Juin, Laurent Maillet. E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell death. Embo Reports First published: 12 December 2017. DOI: 10.15252/embr.201744046 
  • Mathot P, Grandin M, Devailly G, Souaze F, Cahais V, Moran S, Campone M, Herceg Z, Esteller M, Juin P, Mehlen P, Dante R. DNA methylation signal has a major role in the response of human breast cancer cells to the microenvironment. Oncogenesis. 2017 Oct 23;6(10):e390. doi: 10.1038/oncsis.2017.88.
  • Tea I, Martineau E, Antheaume I, Lalande J, Mauve C, Gilard F, Barillé-Nion S, Blackburn AC, Tcherkez G. 13C and 15N natural isotope abundance reflects breast cancer cell metabolism. Sci Rep. 2016 Sep 28;6:34251. doi: 10.1038/srep34251.
  • Chiche A, Moumen M, Romagnoli M, Petit V, Lasla H, Jézéquel P, de la Grange P, Jonkers J, Deugnier MA, Glukhova MA, Faraldo MM. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors. Oncogene. 2017 Apr 27;36(17):2355-2365.
  • Olivier Tasseau, Paul Mosset, Sophie Barillé-Nion, Fabien Gautier, Philippe Juin, Nicolas Levoin, Niharika Amireddy, Shasi Kalivendi, René Grée. Synthesis and cytotoxicity studies of new designed benzyl-hydroquinone derivatives. Medicinal Chemistry Research. Accepted
  • Bagacean C, Tempescul A, Le Dantec C, Bordron A, Mohr A, Saad H, Olivier V,
  • Zdrenghea M, Cristea V, Cartron PF, Douet-Guilbert N, Berthou C, Renaudineau Y. Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia. Oncotarget. 2017 Aug 9;8(39):65699-65716. 
  • Guen VJ, Chavarria TE, Kröger C, Ye X, Weinberg RA, Lees JA. EMT programs promote basal mammary stem cell and tumor-initiating cell stemness by inducing primary ciliogenesis and Hedgehog signaling. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10532-E10539. 
  • Guen VJ, Gamble C, Lees JA, Colas P. The awakening of the CDK10/Cyclin M protein kinase. Oncotarget. 2017 Jul 25;8(30):50174-50186. 
  • Raimbourg J, Joalland MP, Cabart M, de Plater L, Bouquet F, Savina A, Decaudin D, Bennouna J, Vallette FM, Lalier L. Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib. Mol Cancer Ther. 2017 Aug;16(8):1634-1644.

2016

  • Pécot J, Maillet L, Le Pen J, Vuillier C, Trécesson SC, Fétiveau A, Sarosiek KA, Bock FJ, Braun F, Letai A, Tait SWG, Gautier F, Juin PP. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. Cell Rep. 2016 Dec 20;17(12):3347-3358. doi: 10.1016/j.celrep.2016.11.064.
  • Dioum MD, Seck M, Silvestre V, Planchat A, Loquet D, Lohard S, Barille-Nion S, Remaud GS, Robins RJ, Tea I. A Ring-D-Seco-Tetranortriterpenoid from Seeds of Carapa procera Active against Breast Cancer Cell Lines. Planta Med. 2016 May 25. 
  • Montoir D, Barille-Nion S, Tonnerre A, Juin P, Duflos M, Bazin MA. Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90. Eur J Med Chem. 2016 119 :17-33
  • Véquaud E, Desplanques G, Jézéquel P, Juin P, Barillé-Nion S. Survivin contributes to DNA repair by homologous recombination in breast cancer cells. Breast Cancer Res Treat. 2016, 155:53–63.
  • Le Pen J, Maillet L, Sarosiek K, Vuillier C, Gautier F, Montessuit S, Martinou JC, Letaï A, Braun F, Juin P. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL. CDDis 2016, Feb 4;7:e2083.
  • Duy Vo D, Rouaud I, Le Devehat F, Gautier F, Barillé-Nion S, Juin P, Levoin N, Boustie J, Grée R. Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic systems against B16-F0 Melanoma Cancer Cells. Med Chem. 2016 Jan 27;6:19725.
  • Thébault S, Agez M, Chi X, Stojko J, Cura V, Telerman SB, Maillet L, Gautier F, Billas-Massobrio I, Birck C, Troffer-Charlier N, Karafin T, Honoré J, Senff-Ribeiro A, Montessuit S, Johnson CM, Juin P, Cianférani S, Martinou JC, Andrews DW, Amson R, Telerman A, Cavarelli J. TCTP contains a BH3-like domain, which instead of inhibiting, activates Bcl-xL. Sci Rep. 2016 Jan 
  • Breiman A, López Robles MD, Carné Trécesson S, Echasserieau K, Bernardeau K, Drickamer K, Imberty A, Barillé-Nion S, Altare F, Pendu JL. Carcinoma-associated fucosylated antigens are markers of the epithelial state and can contribute to cell adhesion through CLEC17A (Prolectin). Oncotarget. 2016 Feb 18.
  • Das SG, Romagnoli M, Mineva ND, Barillé-Nion S, Jézéquel P, Campone M, Sonenshein GE. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells. Breast Cancer Res. 2016 Apr 2;18(1):40.
  • Moserova I, Truxova I, Garg AD, Tomala J, Agostinis P, Cartron PF, Vosahlikova S, Kovar M, Spisek R, Fucikova J. Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. Oncoimmunology. 2016 Nov 18;6(1):e1258505. 
  • Petit E, Cartron PF, Oliver L, Vallette FM. The phosphorylation of Metaxin 1 controls Bak activation during TNFα induced cell death. Cell Signal. 2017 Jan;30:171-178. 
  • Brenner C, Luciani J, Bizet M, Ndlovu M, Josseaux E, Dedeurwaerder S, Calonne E, Putmans P, Cartron PF, Defrance M, Fuks F, Deplus R. The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent. Oncotarget. 2016 Sep 13;7(37):58939-58952. 
  • Myrianthopoulos V, Cartron PF, Liutkevičiūtė Z, Klimašauskas S, Matulis D, Bronner C, Martinet N, Mikros E. Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation. Eur J Med Chem. 2016 May 23;114:390-6. doi: 10.1016/j.ejmech.2016.02.043. 
  • Guen VJ, Gamble C, Perez DE, Bourassa S, Zappel H, Gärtner J, Lees JA, Colas P. STAR syndrome-associated CDK10/Cyclin M regulates actin network architecture and ciliogenesis. Cell Cycle. 2016;15(5):678-88. 

Offers

If like us, you are interested in understanding cancers and imagining tomorrow’s personalized medicine in oncology, do not hesitate to contact us.

Offers

Master 2

Epithelial plasticity and primary ciliogenesis in breast cancer therapeutic resistance. Under the supervising of Dr Vincent Guen, CR INSERM, vincent.guen@inserm.fr

PhD Thesis

Under the supervising of Dr Vincent Guen, CR INSERM
The title of the proposed thesis is "Investigating the role of the primary cilium in stem cell fate determination in response to stress".
If you are an highly motivated candidate please feel free to directly contact vincent.guen@inserm.fr to postulate or ask more details. 

Post docs

An announcement will be made soon.

Others job opportunities

No specific announcement at the moment.
However, if you are interested in joining the team, please feel free to submit your spontaneous applications to philippe.juin@inserm.fr 

Visit of the lab

One team - Two laboratory sites

 

IRS-UN  Nantes (quai Moncousu)

ICO Site Saint Herblain (boulevard Jacques Monod)

IRS UN Entrée ICO
Cyrometry facility IRS1 Biochemistry 2 experiment_1 Cell culture IRS1_1 IRS1 biochemistry room cell culture room cell culture room _2 Posters cytometry saint herblain Biochemistry